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Abstract 
Background: Very early onset inflammatory bowel disease (VEOIBD) is an umbrella 
term for a heterogeneous group of phenotypes typified by chronic intestinal 
inflammation in children with disease-onset before the sixth year of life. Disease 
stratification poses considerable challenges given the difficulties in integrating 
VEOIBD phenotypes into conventional IBD categories: children are more likely to 
present with more extensive, unclassifiable and treatment-resistant disease when 
compared to adults with IBD. Furthermore, a diverse group of monogenic conditions 
can present with IBD-like intestinal inflammation.  
Design: We retrospectively reviewed phenotype data of VEOIBD patients and 
recruited candidates for Next Generation Sequencing of established VEOIBD genes 
(Whole Exome Sequencing (WES) and Targeted Gene Panel Sequencing (TGPS)).  
Results: Over a period of 15 years, 80 VEOIBD patients (55% male) were managed 
and genetically screened. The median disease onset was six months of age [IQR: 1 to 
22] with 78% developing symptoms before the second year of life (infantile-onset 
IBD). The most common overall diagnosis was IBDU (65%). CD and UC-like IBD were 
diagnosed in 28% and 8% respectively. Eighty-one percent developed pan-colonic 
inflammation, 16% extensive perianal inflammation and 9% stricturing disease. 
Thirty-three percent required parenteral nutrition and 15% underwent abdominal 
surgery. In 28% of children, TNF-alpha blockade with concomitant 
immunomodulator therapy was not sufficient to sustain remission. Hematopoietic 
stem cell transplantation (HSCT) was performed in 23% of patients. Prior to the 
launch of our Next Generation Sequencing (NGS) program, nine patients were 
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diagnosed through Sanger sequencing (genes: IL10, IL10RA, IL10RB, XIAP, IPEX). 
Since then, NGS revealed 10 diagnoses in six genes (EPCAM, IL10RA, TTC37, SKIV2L, 
LRBA, TTC7A).  
Conclusion: Comprehensive immunological, histological and genetic assessment is 
important to support diagnosis and management. Genetic screening is particularly 
advisable in consanguineous patients and children with infantile disease-onset, 
evidence of severe perianal disease, abnormal intestinal epithelial morphology or 
presence of other associated syndromic features. Particularly for children with 
disease-onset before the 2nd year of life, the phenotype heterogeneity is not 
sufficiently addressed by currently available IBD classification tools. 
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Introduction 
Very Early Onset Inflammatory Bowel Disease (VEOIBD) refers to children with 
disease-onset before the sixth year of life 1. This age group represents the minority 
of worldwide reported IBD cases with an estimated incidence of 4.37 per 100000 
children and a prevalence of 14 per 100000 children 2. Consistent with adults with 
IBD, children present with abdominal pain, intestinal bleeding, diarrhoea and weight 
loss 3. Of greater concern in this age group however, are the effects of chronic 
inflammation on growth and global development 4. In paediatric IBD and particularly 
in VEOIBD, it is therefore paramount to establish effective diagnostic and 
management strategies early in the disease course 5. This poses considerable 
challenges given the difficulties in integrating VEOIBD phenotypes into conventional 
IBD categories: children are more likely to present with more extensive, 
unclassifiable and treatment-resistant disease compared to adults with IBD 6 7. IBD 
classification has recently been modified to address the younger age group but this 
might not be sufficient to accommodate the heterogeneous phenotype of VEOIBD 8. 
Some children with IBD-like disease may not benefit from conventional stratification 
into Crohn's disease (CD), ulcerative colitis (UC) or IBD unclassified (IBDU). 
IBD-like intestinal inflammation can also present as a feature of a phenotypically 
diverse group of monogenic conditions including primary immunodeficiencies 
(affecting T/B cells), phagocyte defects, hyper- and autoinflammatory disorders, 
immune regulation- and epithelial barrier defects 9. The majority of monogenic IBD-
like diseases are classified as IBDU due to the lack of pathognomonic features of CD 
or UC 10. Large-scale genetic screening programmes will shed light on the still 
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unknown overall incidence and prevalence of monogenic IBD. The feasibility of 
comprehensive genetic screening in VEOIBD beyond patients with obvious 
syndromic features or consanguineous background has yet to be established 11.  
The aim of this retrospective cohort analysis was to map the heterogeneous 
phenotypes of VEOIBD and to establish new disease stratification tools. In addition, 
we have interrogated the results of a Next Generation Sequencing (NGS) pipeline to 
relate phenotypic data with known genotypes in the largest cohort of genetically 
screened VEOIBD patients reported to date. 
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Methods 
Patient Cohort: 
We retrospectively reviewed case notes, electronic case records and archived 
microfilms from 80 VEOIBD patients who have been managed at Great Ormond 
Street Hospital for Children (GOSH) over the last 15 years. We extracted 
anthropometric data, clinical features and laboratory results at presentation when 
available.  
50/80 patients were diagnosed at our centre with the remaining children having 
undergone primary diagnostic work-up elsewhere. 
Definitions:  
1. Age of onset: time point from birth at which IBD related and/or gastrointestinal 
symptoms became apparent.  
2. VEOIBD: disease with chronic-relapsing gastrointestinal symptoms with 
histological features of chronic with or without acute inflammation of the intestinal 
mucosa (after exclusion of infectious and allergic/eosinophilic intestinal diseases) 
and with symptom-onset before the sixth year of life.  
3. VEOIBD-CD and UC: this study defines children as "CD-like" or “UC-like” based on 
clinical and/or histopathological features (as established elsewhere: see 10) 
regardless of their underlying genetic screening result.  
4. VEOIBD-U: IBD which cannot be classified as CD or UC 10. This heterogeneous 
group contained children with localized or panenteric chronic-with or without acute 
inflammation, evidence of increased apoptotic activity and/or abnormal epithelial 
morphology on histological examination. 
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For anthropometric data and laboratory markers, we only considered values from 
treatment naïve symptomatic patients at the time of diagnostic endoscopy (n=50). 
We prospectively recruited candidates for further molecular evaluation, including 
NGS, as part of the PETIT Study (Patients with Early-onseT Intestinal inflammaTion 
Study).  
NGS: 
In a previous published study we evaluated two different NGS technologies 
(Targeted Gene Panel Sequencing (TGPS) and Whole Exome Sequencing (WES)) to 
screen for mutations in known VEOIBD genes 11. Over a two-year period up to the 
time of writing, 25 patients were recruited for WES and 55 for TGPS (for in-depth 
methodology see: 11). 
Ethical approval: 
Patients were informed and consented for functional studies and NGS as part of the 
“PETIT Study”. Ethical approval was obtained from the National Research Ethics 
Service Committee London, Bloomsbury. 
Statistical analysis: 
IBM SPSS Statistics for Windows, version 22 (Armonk, NY) was used to perform 
statistical analysis. Continuous data is presented as medians with interquartile 
ranges and categorical data is presented as rates and proportions. 
Mann-Whitney U Test and Kruskal-Wallis were used to compare continuous data 
between groups. Spearman's rho was used to interrogate correlation between two 
continuous data sets. To compare proportions between groups we used Pearson Chi-
square and Fisher's Exact Test where appropriate. All tests were two-tailed and 
significance level was set at 5%. 
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Weights were converted to weight-for-age z-scores using WHO Anthro- and WHO 
Anthro Plus software.  
Multiple logistic regression analysis was used to assess the probability of monogenic 
VEOIBD when presented with specific phenotype features. Only variables with p-
values < 0.05 were included in the model. Goodness-of-fit of logistic regression 
model was based on Hosmer-Lemeshow test. 
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Results 
Over the last 15 years, 80 VEOIBD patients were treated at our centre, 55% of whom 
were male. Fifty-four percent of our patients were White Europeans, 14% were 
Middle Eastern/Arab States -, 11% Pakistani-, 8% Indian-, 6% Bangladeshi-, 4% 
African- and 4% of mixed ethnic origin. Twenty-six percent (21/80) were offspring 
from consanguineous unions.  
Overall, 19/80 cases (X%) were associated with specific monogenic mutations. 
Children from consanguineous families had earlier disease onset compared to 
children from non-consanguineous backgrounds (1 month [IQR: 0 to 12] vs. 9 
months [IQR: 3 to 28], p = 0.003) and they had a greater rate of identified monogenic 
VEOIBD (48% (10/21) vs. 15% (9/59), p = 0.006). 
Eighteen per cent of patients had a positive family history for IBD amongst first-
degree relatives and 14% had at least one sibling affected with IBD. The overall 
mortality rate was 4% (1st Patient: IPEX syndrome, idiopathic pneumonitis with 
multiorgan failure 12 months post HSCT; 2nd Patient: XIAP deficiency, progressive JC 
virus encephalitis 28 months post HSCT; 3rd Patient: IL10RA deficiency, pulmonary 
hypertension 6 weeks post HSCT). 
The overall observational period for all 80 patients (first endoscopy to last contact) 
was 28 months [IQR: 14 to 66]. For patients diagnosed at our centre (n=50) the 
median time of observation (diagnostic endoscopy to last contact) was 34 months 
[IQR: 15 to 74].  
Symptoms at presentation: 
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The median disease onset for all 80 patients was six months of age [IQR: 1 to 22] 
with 78% developing symptoms before the second year of life (infantile-onset IBD). 
Figure 1 describes the most common gastrointestinal symptoms at presentation. 
A subgroup of patients exhibited additional atopic features (atopic dermatitis: 20%; 
drug allergy: 14%; food allergy: 10%; asthma: 4%). 
 
 
Figure 1: symptoms reported at diagnosis (in % of cases) for 80 patients with 
VEOIBD. 
Weight-for-age at time of diagnosis: 
At the time of first endoscopy anthropometric data was analysed for all patients 
diagnosed at our centre (n=50). The median weight-for-age z-score was -1.15 [IQR: -
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2.85 to 0.42]. Thirty-two per cent (16/50) of children had moderate or severe 
malnutrition (10 cases below  -3 z-scores).  
Children with earlier disease-onset presented with lower weight-for-age z-scores at 
diagnosis (rho = 0.486, p < 0.0001) but weight-for-age z-scores did not correlate with 
time between disease onset and weight measurement (rho = -0.153, p = 0.366). 
Children with monogenic VEOIBD had lower z-scores at diagnosis (-3.9 [IQR: -4.51 to 
-1.05] vs. -0.97 [IQR: -2.22 to 0.55], p = 0.009). 
 
 
Figure 2: Weight for age z-scores for children diagnosed with CD, UC and IBDU. 
Dotted horizontal lines represent 50th, 9th and 0.4th weight-for-age centiles (no 
statistical difference of median weight and number of malnourished children 
between the three groups). 
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Endoscopic and histological features: 
Patients who had primary diagnostic work up at our centre (n=50) had a median age 
at onset of symptoms of 13 months [IQR: 2 to 29] and underwent endoscopy at a 
median age of 30 months [IQR: 10 to 44]. Longitudinal histology data (diagnostic 
endoscopy to latest endoscopy) for patients diagnosed at our centre was available 
for an observational period of 20 months [IQR 4 to 63]. 
Histological data sets were analysed for all patients in this study (n=80) and 
cumulative endoscopic features were extracted and stratified (Table 1).  
The most common histological pattern was IBDU (65%). Features suggestive of CD 
and UC were diagnosed in 28% and 8% respectively. Age at disease onset differed 
between diagnoses (p = 0.027), with post-hoc analysis revealing a statistically 
significant difference between symptom onset in IBDU and UC (5 months [IQR: 1 to 
16] vs. 23 months [IQR: 14 to 36], p = 0.023). Pancolonic disease was seen in 81% 
with the rates not significantly different amongst the three different histological 
subgroups (UC, CD and IBDU, data not shown). Eleven cases of CD diagnosed at our 
centre developed pancolonic disease; in 10 patients this was already evident at 
diagnostic endoscopy. Furthermore, all four UC patients presented with pancolonic 
disease on diagnostic endoscopy. Eighteen out of 32 IBDU patients diagnosed at our 
centre developed panenteric disease over time. Amongst those, 13 children had 
panenteric inflammation at first (diagnostic) endoscopy. 
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Chronic +/- acute inflammation IBDU (n=52) CD (n=22) UC (n=6) 
Oesophagus 12/52 (23%) 11/22 (50%) 2/6 (33%) 
Stomach 40/52 (77%) 16/22 (73%) 3/6 (50%) 
Duodenum 41/52 (79%) 11/22 50%) 0/6 (0%) 
Terminal Ileum (66/80) 14/39 (36%) 12/22 (55%) 0/5 (0%) 
Pancolonic 43/52 (83%) 16/22 (73%) 6/6 (100%) 
Isolated small bowel 9/52 (17%) 0/22 (0%) 0/6 (0%) 
Small bowel and pancolonic 34/52 (65%) 9/22 (41%) 0/6 (0%) 
Other histological features 
Villus atrophy 20/52 (38%) 4/22 (18%) 0/6 (0%) 
Epithelial abnormalities 9/52 (17%) 0/22 (0%) 0/6 (0%) 
Increased apoptosis 8/52 (15%) 0/22 (0%) 0/6 (0%) 
Granulomata 0/52 (0%) 14/22 (64%) 0/6 (0%) 
Other endoscopic and clinical features 
Perianal 0/52 (0%) 13/22 (59%) 0/6 (0%) 
Stricturing 4/52 (8%) 3/22 (14%) 0/6 (0%) 
Fistulising 0/52 (0%) 2/22 (9%) 0/6 (0%) 
 
Table 1. Cumulative clinical and histological features and anatomical distribution of 
inflammation in patients with IBDU, CD and UC. 
 
Sub-analysis of the IBDU cohort (n=52) revealed that 65% developed panenteric 
disease (inflammation of the upper and lower gastrointestinal tract), 17% had 
exclusively pancolonic and 17% exclusively small bowel disease. Histological features 
only found in the IBDU-panenteric patients were: abnormal epithelial morphology 
(Irregular surface epithelium, tufting-like changes and epithelial cell layer non-
adherent to the basal membrane, n=9) and increased apoptotic activity (n=8). 
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Figure 3. Hematoxylin and eosin stain of intestinal biopsy from patient with TTC7A 
deficiency with evidence of morphologically abnormal epithelium and separation 
with abundance of chronic and acute inflammatory cells in the lamina propria. 
 
Laboratory markers: 
Full blood count, inflammatory markers and albumin levels were available from 
treatment naïve children who underwent primary diagnostic endoscopy at our 
centre (n=50). 
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Figure 4. Scatter plot for laboratory markers measured at diagnosis. Black, filled dots 
represent age-dependant abnormal results. There was no statistically significant 
difference between the three disease groups (haemoglobin, haematocrit, albumin, 
ESR and C-reactive protein) with the exception of raised platelet count (CD-like vs. 
IBDU) and white cell count (CD-like vs. IBDU) (p<0.05)*. 
 
Immunology work-up was reviewed for all patients in our cohort (n=80). Basic 
lymphocyte subsets (CD3+; CD3+CD4+; CD3+CD8+; CD19+ and CD56+CD16+), 
immunoglobulin profiles (IgG, IgA and IgM) and nitro blue tetrazolium chloride test 
results (NBT) for diagnosing chronic granulomatous disease (CGD) could be 
ascertained for 54%, 70% and 34% of patients respectively. All NBT test results were 
normal.  
Total IgE was measured in 73% of children. In 31% of cases (18/58), total IgE was 
above the upper limit of normal range (adjusted to varying normal range: exceeding 
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the upper limit of normal range by 257% [IQR: 24% to 545%]). All three children with 
IPEX disease presented with high IgE levels (282 i/U, 369 i/U and 34404 i/U). 
Transient hypogammaglobulinaemia (with concomitant low serum albumin levels) in 
patients with acute intestinal inflammation was observed in 14% of patients (median 
% below normal range was 29 [IRQ: 19 to 54%]). Five patients were found to have 
consistently abnormal immunology profiles: One patient with LRBA-deficiency 
presented with abnormally raised γδ-cells on T-cell panel (after alternative T-cell 
expansion was suspected on basic lymphocyte subset panel). Two TTC7A deficient 
patients presented with lower than normal T-cell counts (reduced total CD3+ and 
CD4+ cells respectively) in addition to low IgA levels in the former patient. One 
patient with negative genetic screening was found to have persistently reverse 
CD4+/CD8+ ratio. 
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Genetics: 
Genetic screening in 80 VEOIBD patients revealed 19 positive cases (24%). Overall, 
children with monogenic VEOIBD developed symptoms earlier when compared with 
the screening negative cohort (1 month [IQR: 0 to 4] vs. 12 months [IQR: 3 to 29], p < 
0.0001). 
 
Figure 5. Onset of disease of all 19 monogenic VEOIBD cases versus screening 
negative patients (for detailed mutation description see supplement 1). 
 
Prior to the launch of the PETIT Study, nine patients were diagnosed through Sanger 
sequencing (causative mutations established in five genes: IL10, IL10RA, IL10RB, 
XIAP, IPEX). Since then, NGS (TGPS and/or WES) revealed nine new diagnoses in six 
genes (EPCAM, IL10RA, TTC37, SKIV2L, LRBA, TTC7A) 9 5. One patient with TTC7A 
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deficiency was diagnosed externally by Sanger Sequencing (for detailed genetic data 
see supplement 1). 
To establish the likelihood of underlying monogenic disease, we have interrogated 
the following phenotypic variables: age at onset, gender, consanguinity, positive 
family history, symptoms at presentation (see figure 1), disease distribution and 
specific histological features (see table 1).  
The logistic regression model (Figure 5) predicts the likelihood of underlying 
monogenic disease when interrogating the three most significant variables (Hosmer-
Lemeshow: p = 0.621): combined model: factor B: -3.264, significance < 0.0001, 
EXP(B) = 0.038), disease onset ≤ 6 month of age (B = 1.864, significance = 0.028, 
EXP(B) = 6.45), histological evidence of abnormal epithelial morphology (B = 3.479, 
significance = 0.003, EXP(B) = 32.439) and the presence of perianal disease 
(abscesses, fistulae and inflamed skin tags; B = 1.526, significance = 0.045, EXP-B = 
4.60).  
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Supplement 1. 80 VEOIBD patients harboured 19 disease-causing mutations. 
(Patients 6-11, 17, 19 previously reported 11-14). HOM: homozygous, CH: compound 
heterozygous, HZ: hemizygous. 
 
 
 
 
Figure 6. Likelihood of underlying causative mutations in patients with VEOIBD based 
on phenotype data from patients managed at our gastroenterology centre  – 
multiple logistic regression model. 
 
Medicines in VEOIBD: 
Medications used to treat VEOIBD included corticosteroids (86%), 
immunomodulators (85%; azathioprine, 6-MP, methotrexate, cyclosporine, 
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tacrolimus, sirolimus or thalidomide), salicylates (48%) and biologics (39%; 
infliximab, adalimumab or basiliximab).  
In addition to TNFα blockade (infliximab, adalimumab) and one first line 
immunosuppressant drug (azathioprine, 6-mercaptopurine or methotrexate), 28% of 
patients received further immunomodulation throughout their monitored disease 
course (≥3 Immunosuppressant Agents (ISA) = ISA ≥3). This cohort of children (ISA 
≥3) did not have earlier onset of disease (6 months vs. 7 months p = 0.791), did not 
receive parenteral nutrition significantly more frequently (41% vs. 29%, p = 0.323) 
and did not have a significantly increased likelihood of harbouring mutations in 
known VEOIBD genes (27% vs. 22%, p = 0.648) than the group of children on two or 
less immunomodulators/biologics (≤2 ISA). 
Children requiring ≥3 ISA did not have significantly longer disease duration (age at 
onset of symptoms to last contact) comparing to children who required ≤2 ISA (72 
months [IQR: 57 to 107] vs. 49 months [IQR: 27 to 87], p = 0.075).  
Parenteral nutrition in VEOIBD: 
A third of children (33%) required parenteral nutrition (PN) throughout their 
monitored disease course (≥ 50% of calorie requirement for ≥ 28 days; introduced 
for enteral food intolerance/gut rest and/or inadequate weight gain). Patients who 
required PN had earlier disease-onset when compared to the non-PN group (1 
month [IQR: 0 to 4] vs. 15 months [IQR: 4 to 31], p < 0.0001). 
Haematopoietic Stem Cell Transplantation in VEOIBD: 
Hematopoietic stem cell transplantation (HSCT) was performed in 18 children of 
whom 14 were transplanted for failure to conventional treatment, three with a 
prior-known HSCT-amenable genetic diagnosis (IPEX and IL10/RA deficiency) and one 
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gene-screening negative patient with a concomitant diagnosis of acute myeloid 
leukaemia. Two patients in our cohort are currently undergoing HSCT work-up. 
Patients who underwent HSCT had earlier disease-onset (2 months [IQR: 0 to 5] vs. 
12 months [IQR: 2 to 28], p = 0.004) and more intensive immunosuppression (ISA ≥3) 
when compared to the cohort of non-transplanted children (61% vs. 18%, p = 001). 
Surgery: 
Fifteen per cent (12/80) of patients underwent abdominal surgery: hemi/subtotal 
colectomy with stoma formation (n=8), stoma formation alone (n=3), surgery for 
isolated small bowel atresias (n=1). Eighteen per cent of children had percutaneous 
gastrostomy tube insertion.  
Summary of treatment strategies: 
Forty-two children were considered the most treatment resistant requiring 
parenteral nutrition, abdominal surgery or extensive immunosuppression (ISA ≥3) 
throughout the observed time period. Figure 6 depicts the application of those three 
treatments in this most resistant treatment group (n=42) sub-classified into three 
histological phenotypes: CD-like, UC-like and IBDU.  
 
 
Figure 7. VEOIBD patients (n=42) with disease phenotype requiring intensified 
management defined as need for 6A: parenteral nutrition (PN), 6B: ISA ≥3 or 6C: 
abdominal surgery. There was no statistically significant difference between the 
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three disease groups and treatment strategies with the exception of the need for 
surgery (CD-like vs. IBDU).   
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Discussion 
In this retrospective cohort study we aimed to fine-map VEOIBD phenotypes in order 
to evaluate potential disease stratifying tools. VEOIBD is different from conventional 
(adult onset/idiopathic) IBD: Children have more disseminated intestinal 
inflammation, higher rates of treatment resistance and rapid disease progression 15 
7. Within this age group, categorizing IBD by means of clinical severity scores 
(Paediatric CD Activity Index or Paediatric UC Activity Index) or anatomical 
distribution (Paris Classification) is difficult and applying such scores presumes 
histological differentiation into CD or UC, which is often not apparent in VEOIBD. 
Consistent with previously published paediatric reports, VEOIBD patients present 
with diarrhoea, abdominal pain, weight loss and rectal bleeding 3. Extended disease 
at presentation has profound effects on growth and weight gain as confirmed in our 
study: 30% of children presented with moderate to severe weight impairment 
(below -2 z-scores weight-for-age). Chronic inflammation has a significant effect on 
the patients' nutritional status as evidenced in our study by the high prevalence of 
hypoalbuminaemia (32%) and anaemia (62% of patients were anaemic at the time of 
diagnosis) 16. 
Inflammatory Markers and Immune Screening: 
To support the clinical suspicion of VEOIBD we interrogated three commonly 
available inflammatory markers: C-reactive protein (CRP), erythrocyte sedimentation 
rate (ESR) and thrombocytosis. In our cohort, ESR was raised in 65% of VEOIBD cases 
being the most frequently abnormal systemic marker for intestinal inflammation 
when compared to thrombocytosis (38%) and raised CRP (18%). This differs from the 
trend seen in conventional IBD 17 18.  
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Performing basic immune screening in our patients had minimal diagnostic benefit. 
There is however a strong argument to investigate basic immune components and 
function given that numerous primary immune deficiencies can present with IBD-like 
disease 5 9.  
Molecular analysis revealed one patient with combined immune deficiency (CID) due 
to LRBA-deficiency (LPS-responsive beige-like anchor). The patient presented with 
chronic diarrhoea, evidence of intestinal inflammation, pancytopenia and mildly 
abnormal basic immune work-up (similar phenotype described in 19): Albeit normal 
CD4+ and CD8+ cell counts the sum of both fractions fell short of the total CD3+ 
count suggesting an expansion of an additional CD3+ cell line. Extended T-cell 
phenotyping established an increased γδ-T-cell fraction raising the possibility of an 
immune dysregularory process secondary to defects in recombination or apoptosis 
pathways. The final diagnosis was established by NGS and confirmed by immunoblot 
(data not shown). LRBA-deficiency has been previously reported to present with IBD-
like disease as well as result in an IPEX phenotype 20 19.  
All three IPEX patients (due to FOXP3 mutations) in our cohort presented with 
unremarkable lymphocyte subsets and significantly raised total IgE consistent with 
previous reports 21. TTC7A deficiency has been recently recognised to cause VEOIBD 
22. It has also been established that patients with TTC7A deficiency can suffer from a 
wide range of immunological abnormalities including SCID-like disease 23. Two 
TTC7A-deficient patients in our cohort presented with low T-cell counts (decreased 
CD4+ cells and decreased CD3+ cells) as well as persistently low IgA levels in one 
child. One patient with negative genetic screening, exhibited persistent reversal of 
the CD4/8 ratio, possibly due to concomitant chronic EBV infection.  
 26 
It is well established that VEOIBD patients can suffer from immune dysregulation, 
which is not necessarily reflected by aberrations of basic immune screening tests: 
Some conditions require specific functional analysis in order to confirm suspected 
defects in pathways as seen in IL10 pathway- or XIAP- deficiency 5 14 24 25.  
Histological examination: 
The high prevalence of pancolonic disease and increased rate of IBDU in the 
paediatric population has been previously described and is confirmed in the present 
study 6 26. Pancolonic disease was present in 81% of all cases. Forty-one percent of 
unclassifiable VEOIBD presented with panenteric inflammation at diagnosis. 
In 2013, the European Society of Paediatric Gastroenterology, Hepatology and 
Nutrition (ESPGHAN) published a widely adopted approach to diagnosing suspected 
paediatric IBD 10. When interrogating our cohort only 35% presented with features 
consistent with either CD (n=22) or UC (n=6). In addition, already sparsely prevalent 
CD-pathognomonic features such as perianal/fistulising disease (16%, 13/80 of 
cases) and granulomata on histology (18%, 14/80 of cases) have also been reported 
in a variety of monogenic conditions such as Chronic Granulomatous Disease (CGD), 
IPEX, XIAP- or IL10 pathway deficiency and can therefore not reliably be considered 
specific for idiopathic CD in this age group 27 28 14 25. As expected, our group of 
patients originally diagnosed with early onset CD contained all five children with IL10 
pathway defects. The heterogeneous group of unclassifiable VEOIBD constitutes the 
largest group in our study and probably the most challenging both, in terms of 
establishing a molecular diagnosis and clinical management (A general diagnostic 
approach to confirm monogenic VEOIBD can be found here 5). 
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In this group of children, microscopic mucosal assessment revealed a distinct 
subgroup of children with abnormal epithelial morphology and concomitant chronic 
or acute on chronic mucosal inflammatory cell infiltration. This feature carried a high 
positive predictive value and should prompt the physician to consider screening for 
genes involved in epithelial integrity 22 29. As previously reported, very early onset 
intestinal inflammation can be due to causative EPCAM mutations, which result in 
tufting enteropathy (TE). The epithelial changes in TE can initially be localised and 
subtle with inflammatory cell infiltration being a dominant feature. In these cases, 
inclusive genetic screening might reveal unexpected molecular diagnoses 30 11. 
Mutations in the gene TTC7A have recently been reported to cause IBD in children 
with stricturing intestinal disease and severe epithelial abnormalities on histology 22 
23. Abnormal epithelial morphology and increased apoptotic activity was evident in 
all three of our patients. Prominent epithelial surface irregularities and increased 
apoptotic activity were also present in our patients with SKIV2L and TTC37 
mutations. Causative variants in TTC37 and SKIV2L genes, both involved in the RNA 
decay pathway of the cell (exosome complex) 31 have previously been reported to 
cause tricho-hepato-enteric syndrome (THES) 32 33.  
Genetic Screening: 
Monogenic conditions with IBD phenotype are commonly inherited in autosomal 
recessive fashion 5 and therefore not surprisingly, are enriched in the cohort of 
children from consanguineous unions. As an international referral centre, our cohort 
is subject to referral bias and as a consequence might over-represent ethnic 
populations with higher prevalence of consanguinity. An increased pre-test 
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probability will therefore overestimate the prevalence of monogenic IBD as 
compared to population-based studies.  
However, our experience and previously published data suggests that 
comprehensive genetic screening regardless of consanguinity or ethnicity can reveal 
unexpected genotypes 11. Given the large number of potential candidate genes and 
overlapping phenotypes, single gene sequencing appears less and less appropriate in 
cases with VEOIBD. The availability and processing time of NGS in the diagnostic 
setting has improved making it the modality of choice for most paediatric 
gastroenterology centres.  In figure 4 we present a logistic regression model, which 
estimates the probability of screening positive for monogenic IBD based on three 
variables: onset of disease younger then 6 months, perianal disease and abnormal 
epithelial morphology. In the absence of specific syndrome-associated features such 
as extensive eczema and diabetes mellitus in patients with FOXP3 mutations it 
might, according to our model, be reasonable to prioritise children with early disease 
onset and abnormal epithelial morphology or perianal disease for prompt genetic 
screening. Exclusively screening the infantile IBD subgroup would however not 
account for the numerous IBD associated monogenic diseases, which can present 
beyond infancy and childhood best exemplified by late-onset XIAP deficiency in 
patients with CD-like phenotype 24.  
Establishing a genetic diagnosis has obvious advantages and potentially enables the 
physician to tailor treatment, predict outcome and counsel patient and parents 
effectively. For example, genetic screening might reveal genotypes amenable for 
HSCT in patients with primary immune deficiencies/dysregulation syndromes 13 21 34 
offering a potentially curative treatment option. 
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Surgical and Medical Management: 
Surgical intervention was required in 15% of our patients. All three patients with 
TTC7A deficiency required bowel resections and stoma formation as previously 
reported in the literature 22 23. From five children with IL10 pathway deficiency, three 
required extensive abdominal surgery; two were diagnosed within months after 
presentation and underwent HSCT prior to needing intensification of medical or 
surgical management 13 12. Three children with no genetic diagnosis underwent 
abdominal surgery and eventually HSCT for uncontrollable disease.  
Similar to conventional IBD, the majority of VEOIBD patients have been exposed to 
steroids (86%) in addition to immunomodulators (85%) and TNFα blockade (39%) as 
long-term therapies. In addition, approximately half of the patients in our cohort 
required parenteral nutrition, abdominal surgery or further escalation of medical 
therapy to control disease (figure 6). This is in keeping with previously published 
data highlighting IBD in this age group as particularly therapy resistant 35 36 37. 
Children with symptom onset in infancy and unclassified panenteric inflammation 
had an increased requirement for PN and escalation of medical treatment. In this 
sub group, we retrospectively established causative mutations in genes involved in 
epithelial barrier integrity (EPCAM and TTC7A) as well as in the RNA-decay pathway 
(SKIV2L and TTC37). Confirming the genotype even in these conditions currently 
lacking well-established treatment options enables the physician to offer less 
conventional treatments and facilitates the sharing of disease-specific management 
experience with the national and international expert community for the benefit of 
the patient. 
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Stratifying VEOIBD: 
Stratifying VEOIBD by establishing a molecular basis was successful in 24% of our 
patients. Our cohort contained only a small proportion of classifiable patients (CD 
and UC). Conventional IBD classification is difficult to apply in infants and very young 
children with IBD: VEOIBD has been established as an umbrella term for diseases 
with chronic intestinal inflammation in childhood, which may or may not resemble 
or in time evolve into conventional IBD 5 1. 
As previously shown, our data suggests that infants with features suggestive of 
perianal-fistulising CD-like disease benefit from genetic screening to investigate, 
amongst others, mutations in the IL10-pathway.  
In the present cohort, we only observed a small number of patients with UC-like IBD 
(n=6) and none harboured causative mutations in known VEOIBD genes. All patients 
presented with pancolonic disease and symptom onset was significantly later when 
compared to the IBDU cohort. 
VEOIBD unclassified comprises a multitude of conditions such as apoptotic 
enterocolitis (e.g. TTC7A deficiency), autoimmune enteropathy (e.g. IPEX and IPEX-
like syndromes), tufting enteropathy (EPCAM deficiency), THES (TTC37 and SKIV2L 
deficiency) as well as others yet undefined chronic intestinal inflammatory 
conditions. Autoimmune diseases which affect the gut (e.g. causative mutations in 
the genes FOXP3, STAT1 and IL2R or LRBA) present with concomitant autoimmune 
features such as diabetes mellitus, thyroid disease, adrenal insufficiency or 
cytopenias 38 39 40 20. In our cohort, genetic screening revealed mutations in the 
FOXP3 and LRBA gene in four patients who also expressed autoimmune features. A 
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large cohort of children with unclassified VEOIBD however, lacked evidence of 
autoimmunity could not be further classified based on clinical, histological, 
laboratory markers 41 nor harboured likely disease-causing mutations in known 
VEOIBD genes. The value of anti-enterocyte antibodies (unavailable in our cohort) 
might provide further evidence of autoimmunity. Doubts remain regarding their 
sensitivity and whether they merely are a secondary phenomenon after mucosal 
damage in some individuals 42. 
Conclusion 
Children with VEOIBD present with clinical and laboratory features reminiscent of 
conventional IBD but suffer from particularly extensive and treatment resistant 
disease. Particularly children with symptom-onset before the 2nd year of life should 
be undergo comprehensive immunological and genetic screening and a diagnosis 
beyond conventional IBD should be considered. We have previously suggested a 
mnemonic for features associated with monogenic IBD (YOUNG AGE MATTERS 
MOST: YOUNG AGE onset, Multiple family members and consanguinity, 
Autoimmunity, Thriving failure, Treatment with conventional medication fails, 
Endocrine concerns, Recurrent infections or unexplained fever, Severe perianal 
disease, Macrophage activation syndrome and hemophagocytic lymphohistiocytosis, 
Obstruction and atresia of intestine, Skin lesions and dental and hair abnormalities, 
and Tumors) 5. 
Currently available classification tools are insufficiently addressing the 
heterogeneous phenotype of these patients and it is therefore advisable to have a 
low threshold for revision of conventional disease terminology. Choosing descriptive 
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disease terminology might therefore be more appropriate considering the 
heterogenetic and unpredictable disease evolution of VEOIBD.  
 
Key messages: 
 VEOIBD is an umbrella term for a heterogeneous group of children presenting 
with evidence of chronic-relapsing intestinal inflammation. 
 VEOIBD patients frequently suffer from severe and treatment unresponsive 
disease. 
 Comprehensive immunological, histological and genetic assessment is 
important to support diagnosis and management. 
 Genetic screening is particularly advisable in consanguineous patients and 
children with infantile disease-onset, evidence of severe perianal disease, 
abnormal intestinal epithelial morphology or presence of other associated 
syndromic features. 
 Particularly for children with disease-onset before the 2nd year of life, the 
phenotype heterogeneity is not sufficiently addressed by currently available 
IBD classification tools. 
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